David Heppner

Has grant

Assistant Professor

University at Buffalo

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

David Heppner is an Assistant Professor at the University at Buffalo, USA. His research focuses on targeted covalent inhibitors, structural analysis of drug interactions, and the structural biology underlying drug discovery and development. He has contributed to the field through various articles that explore the mechanisms of EGFR inhibitors and the impact of NIH indirect cost cuts on drug development.

Recent Grants

Grant: Close

Investigations of Redox-dependent Processes of the Airway Epithelium

Open Date: 2016-07-01

Close Date: 2017-10-31

Articles (22)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (7)

Andrew Murkin

Associate Professor

University at Buffalo - North Campus

UNITED STATES

View details

Anna Schmoker

Dana-Farber Cancer Institute

UNITED STATES

View details

Florian Wittlinger

Eberhard Karls Universität Tübingen

GERMANY

View details

William Feng

Dana-Farber Cancer Institute

UNITED STATES

View details

Matthias Gehringer

Eberhard Karls Universität Tübingen

GERMANY

View details

Tyler Beyett

Assistant Professor

Emory University

UNITED STATES

View details

David Scott

Dana-Farber Cancer Institute

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

David Heppner

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (22)

Profiling and Optimizing Targeted Covalent Inhibitors through EGFR-Guided Studies

Structure–Activity Relationships of Inactive‐Conformation Binding EGFR Inhibitors: Linking the ATP and Allosteric Pockets

Ascertaining a Structural Basis in Drug Discovery and Development

Drug Discovery and Development Faces an Ominous Future from NIH Indirect Costs Rate Cuts

Introduction to the themed collection on kinases

Lazertinib: breaking the mold of third-generation EGFR inhibitors

Demystifying Functional Parameters for Irreversible Enzyme Inhibitors

Structural Biology in Drug Discovery and Development: Call for Papers

Structural Biology in Drug Discovery and Development: Call for Papers

Structural Analysis of the Macrocyclic Inhibitor BI‐4020 Binding to EGFR Kinase

Pitfalls and Considerations in Determining the Potency and Mutant Selectivity of Covalent Epidermal Growth Factor Receptor Inhibitors

Inhibition of a lower potency target drives the anticancer activity of a clinical p38 inhibitor

An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer

Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448)

Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors

Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC

Architecture of the NADPH oxidase family of enzymes

Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors

Design of a “Two-in-One” Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites

A structural perspective on targeting the RTK/Ras/MAP kinase pathway in cancer

Oxidation–Dependent Activation of Src Kinase Mediates Epithelial IL-33 Production and Signaling during Acute Airway Allergen Challenge

Structural insights into redox-active cysteine residues of the Src family kinases

Collaborators (7)

Andrew Murkin

Anna Schmoker

Florian Wittlinger

William Feng

Matthias Gehringer

Tyler Beyett

David Scott

Make your next move.